Miguel Angel Ramos-Méndez, Carlos Alfonso Tovilla-Zárate, Isela Esther Juárez-Rojop, Mario Villar-Soto, Alma Delia Genis-Mendoza, Thelma Beatriz González-Castro, María Lilia López-Narváez, José Jaime Martínez-Magaña, Rosa Giannina Castillo-Avila, Guillermo Efrén Villar-Juárez
{"title":"利培酮对精神分裂症患者血清IL-6水平的影响:一项系统回顾和荟萃分析","authors":"Miguel Angel Ramos-Méndez, Carlos Alfonso Tovilla-Zárate, Isela Esther Juárez-Rojop, Mario Villar-Soto, Alma Delia Genis-Mendoza, Thelma Beatriz González-Castro, María Lilia López-Narváez, José Jaime Martínez-Magaña, Rosa Giannina Castillo-Avila, Guillermo Efrén Villar-Juárez","doi":"10.1080/13651501.2022.2100264","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Risperidone has been significant correlated with a direct effect of interleukin-6 (IL-6) levels in patients with schizophrenia. This fact allows the opportunity to link the probable immunomodulatory effect of antipsychotic medication. Specially, a proper functioning of IL-6 pathway plays a potential role in the treatment or development of schizophrenia.</p><p><strong>Objective: </strong>Our primary aim was to perform a systematic review and meta-analysis to determine the effect of risperidone on IL-6 levels in individuals with schizophrenia.</p><p><strong>Methods: </strong>Studies were identified through a systematic search using PubMed, Scopus, and Web of Science databases. The articles found were subjected to the inclusion and exclusion criteria; then, the mean and standardised differences were extracted to calculate the standardised mean differences using the CMA software.</p><p><strong>Results: </strong>IL-6 levels in individuals with schizophrenia were compared before and after receiving risperidone as treatment. Increased levels of IL-6 levels were observed in individuals with schizophrenia who received risperidone (point estimate 0.249, lower limit 0.042, upper limit 0.455, <i>p</i>-value 0.018). In the Asian population sub-analysis, no statistically significant differences were observed (point estimate 0.103, lower limit -0.187, upper limit 0.215, <i>p</i> value 0.890). When we compared individuals with schizophrenia to the control groups, a significant increase of IL-6 levels was observed in the group with schizophrenia (point estimate 0.248, lower limit 0.024, upper limit 0.472, <i>p</i>-value 0.30).</p><p><strong>Conclusions: </strong>Risperidone appears to play an important role in IL-6 levels in schizophrenia. Potential implications of increased IL-6 levels in people with schizophrenia should be considered in future studies.KEY POINTSIncreased levels of IL-6 levels were observed in individuals with schizophrenia who received risperidone.Risperidone appears to play an important role in IL-6 levels in schizophrenia.This study could serve for future research focussed on IL-6.</p>","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":"27 2","pages":"171-178"},"PeriodicalIF":2.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis.\",\"authors\":\"Miguel Angel Ramos-Méndez, Carlos Alfonso Tovilla-Zárate, Isela Esther Juárez-Rojop, Mario Villar-Soto, Alma Delia Genis-Mendoza, Thelma Beatriz González-Castro, María Lilia López-Narváez, José Jaime Martínez-Magaña, Rosa Giannina Castillo-Avila, Guillermo Efrén Villar-Juárez\",\"doi\":\"10.1080/13651501.2022.2100264\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Risperidone has been significant correlated with a direct effect of interleukin-6 (IL-6) levels in patients with schizophrenia. This fact allows the opportunity to link the probable immunomodulatory effect of antipsychotic medication. Specially, a proper functioning of IL-6 pathway plays a potential role in the treatment or development of schizophrenia.</p><p><strong>Objective: </strong>Our primary aim was to perform a systematic review and meta-analysis to determine the effect of risperidone on IL-6 levels in individuals with schizophrenia.</p><p><strong>Methods: </strong>Studies were identified through a systematic search using PubMed, Scopus, and Web of Science databases. The articles found were subjected to the inclusion and exclusion criteria; then, the mean and standardised differences were extracted to calculate the standardised mean differences using the CMA software.</p><p><strong>Results: </strong>IL-6 levels in individuals with schizophrenia were compared before and after receiving risperidone as treatment. Increased levels of IL-6 levels were observed in individuals with schizophrenia who received risperidone (point estimate 0.249, lower limit 0.042, upper limit 0.455, <i>p</i>-value 0.018). In the Asian population sub-analysis, no statistically significant differences were observed (point estimate 0.103, lower limit -0.187, upper limit 0.215, <i>p</i> value 0.890). When we compared individuals with schizophrenia to the control groups, a significant increase of IL-6 levels was observed in the group with schizophrenia (point estimate 0.248, lower limit 0.024, upper limit 0.472, <i>p</i>-value 0.30).</p><p><strong>Conclusions: </strong>Risperidone appears to play an important role in IL-6 levels in schizophrenia. Potential implications of increased IL-6 levels in people with schizophrenia should be considered in future studies.KEY POINTSIncreased levels of IL-6 levels were observed in individuals with schizophrenia who received risperidone.Risperidone appears to play an important role in IL-6 levels in schizophrenia.This study could serve for future research focussed on IL-6.</p>\",\"PeriodicalId\":14351,\"journal\":{\"name\":\"International Journal of Psychiatry in Clinical Practice\",\"volume\":\"27 2\",\"pages\":\"171-178\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Psychiatry in Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13651501.2022.2100264\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13651501.2022.2100264","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 1
摘要
背景:利培酮与精神分裂症患者白细胞介素-6 (IL-6)水平的直接影响显著相关。这一事实使我们有机会将抗精神病药物可能的免疫调节作用联系起来。特别是，IL-6通路的正常运作在精神分裂症的治疗或发展中起着潜在的作用。目的:我们的主要目的是进行系统回顾和荟萃分析，以确定利培酮对精神分裂症患者IL-6水平的影响。方法:通过使用PubMed、Scopus和Web of Science数据库进行系统搜索来确定研究。所发现的物品符合纳入和排除标准;然后，提取均值和标准化差值，利用CMA软件计算标准化均值差。结果:比较利培酮治疗前后精神分裂症患者IL-6水平。接受利培酮治疗的精神分裂症患者IL-6水平升高(点估计0.249，下限0.042，上限0.455,p值0.018)。在亚洲人群亚组分析中，差异无统计学意义(点估计0.103，下限-0.187，上限0.215,p值0.890)。当我们将精神分裂症个体与对照组进行比较时，观察到精神分裂症组IL-6水平显著升高(点估计0.248，下限0.024，上限0.472,p值0.30)。结论:利培酮似乎在精神分裂症患者IL-6水平中起重要作用。在未来的研究中应考虑到精神分裂症患者IL-6水平升高的潜在影响。在接受利培酮治疗的精神分裂症患者中观察到IL-6水平升高。利培酮似乎在精神分裂症患者IL-6水平中起重要作用。本研究可为今后对IL-6的研究提供参考。
Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis.
Background: Risperidone has been significant correlated with a direct effect of interleukin-6 (IL-6) levels in patients with schizophrenia. This fact allows the opportunity to link the probable immunomodulatory effect of antipsychotic medication. Specially, a proper functioning of IL-6 pathway plays a potential role in the treatment or development of schizophrenia.
Objective: Our primary aim was to perform a systematic review and meta-analysis to determine the effect of risperidone on IL-6 levels in individuals with schizophrenia.
Methods: Studies were identified through a systematic search using PubMed, Scopus, and Web of Science databases. The articles found were subjected to the inclusion and exclusion criteria; then, the mean and standardised differences were extracted to calculate the standardised mean differences using the CMA software.
Results: IL-6 levels in individuals with schizophrenia were compared before and after receiving risperidone as treatment. Increased levels of IL-6 levels were observed in individuals with schizophrenia who received risperidone (point estimate 0.249, lower limit 0.042, upper limit 0.455, p-value 0.018). In the Asian population sub-analysis, no statistically significant differences were observed (point estimate 0.103, lower limit -0.187, upper limit 0.215, p value 0.890). When we compared individuals with schizophrenia to the control groups, a significant increase of IL-6 levels was observed in the group with schizophrenia (point estimate 0.248, lower limit 0.024, upper limit 0.472, p-value 0.30).
Conclusions: Risperidone appears to play an important role in IL-6 levels in schizophrenia. Potential implications of increased IL-6 levels in people with schizophrenia should be considered in future studies.KEY POINTSIncreased levels of IL-6 levels were observed in individuals with schizophrenia who received risperidone.Risperidone appears to play an important role in IL-6 levels in schizophrenia.This study could serve for future research focussed on IL-6.
期刊介绍：
International Journal of Psychiatry in Clinical Practice provides an international forum for communication among health professionals with clinical, academic and research interests in psychiatry.
The journal gives particular emphasis to papers that integrate the findings of academic research into realities of clinical practice.
Focus on the practical aspects of managing and treating patients.
Essential reading for the busy psychiatrist, trainee and interested physician.
Includes original research papers, comprehensive review articles and short communications.
Key words: Psychiatry, Neuropsychopharmacology, Mental health, Neuropsychiatry, Clinical Neurophysiology, Psychophysiology, Psychotherapy, Addiction, Schizophrenia, Depression, Bipolar Disorders and Anxiety.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
